<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085812</url>
  </required_header>
  <id_info>
    <org_study_id>LVM-MD-05</org_study_id>
    <nct_id>NCT01085812</nct_id>
  </id_info>
  <brief_title>Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER
      relative to placebo in the prevention of depression relapse in patients with major depressive
      disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week
      open-label treatment period with Levomilnacipran ER are randomized to continue
      Levomilnacipran ER or switch to placebo under double-blind conditions for up to 24 weeks of
      additional treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse (Days)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of days until patients meet relapse criteria. Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">734</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules, oral administration, once daily dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levomilnacipran ER</intervention_name>
    <description>Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to be given orally, in capsule form, once daily.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18-65 years old

          -  Currently meet the DSM-IV-TR criteria for Major Depressive Disorder

          -  The patient's current depressive episode must be at least 4 weeks in duration

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women
             with childbearing potential who are not practicing a reliable method of birth control

          -  Patients with a history of meeting DSM-IV-TR criteria for:

               -  any manic or hypomanic episode

               -  schizophrenia or any other psychotic disorder

               -  obsessive-compulsive disorder

          -  Patients who are considered a suicide risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanna Forero, MA</last_name>
    <role>Study Director</role>
    <affiliation>Forest Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site #023</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #017</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>31316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #021</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #025</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #030</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #002</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #003</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Research Institute #001</name>
      <address>
        <city>Bonita Springs</city>
        <state>Florida</state>
        <zip>34134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #015</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #029</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #005</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #016</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #004</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #014</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #022</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #006</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #009</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #013</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #010</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #012</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #011</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #026</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #008</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <zip>15017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #028</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #020</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #024</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #007</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #019</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #018</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #027</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #050</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #051</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #052</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1S 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #055</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7M 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site #053</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <results_first_submitted>August 22, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <disposition_first_submitted>December 29, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 29, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 4, 2012</disposition_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Levomilnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient were recruited over a 10-month period from March of 2010 to January of 2011 at 36 studies sites, 30 in the United States and 6 in Canada.</recruitment_details>
      <pre_assignment_details>Patients began with a 12-week open-label treatment period, followed by a 24-week double-blind treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo capsules, oral administration, once daily dosing.</description>
        </group>
        <group group_id="P2">
          <title>Levomilnacipran ER</title>
          <description>40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="734"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Intent-to-treat Population</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive serum pregnancy test result</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Participant population is based on the 734 enrolled patients who received at least one dose of open-label treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Open Label Levomilnacipran ER</title>
          <description>40, 80 or 120 mg Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="734"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 years to 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 years to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 years to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 years to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 years to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 years to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="425"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.41" spread="18.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilograms Per Meter Squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.88" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse (Days)</title>
        <description>Number of days until patients meet relapse criteria. Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4</description>
        <time_frame>24 Weeks</time_frame>
        <population>The double blind Intent-to-treat population consists of 342 randomized participants who received study drug and were evaluated for the Primary Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo capsules, oral administration, once daily dosing.</description>
          </group>
          <group group_id="O2">
            <title>Levomilnacipran ER</title>
            <description>40, 80 or 120 mg Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse (Days)</title>
          <description>Number of days until patients meet relapse criteria. Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4</description>
          <population>The double blind Intent-to-treat population consists of 342 randomized participants who received study drug and were evaluated for the Primary Outcome Measure</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Relapse did not occur within the 24-week time frame of the study</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Relapse did not occur within the 24-week time frame of the study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collection over a 20-month period from March 2010 to November 2011 at 36 study sites in the U.S and Canada.</time_frame>
      <desc>The Serious Adverse Event data presented here is for the safety population. The Other Adverse Event data presented here is for the safety population during the 24 week double-blind treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label Levomilnacipran ER</title>
          <description>40, 80 or 120 mg Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Double Blind Treatment</title>
          <description>Matching placebo capsules, oral administration, once daily dosing.</description>
        </group>
        <group group_id="E3">
          <title>Levomilnacipran ER - Double Blind Treatment</title>
          <description>40, 80 or 120 mg Levomilnacipran ER capsules, oral administration, once daily dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="448" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a failed study. The lower than expected rate of relapse in the placebo group compromised the projected power to demonstrate a difference between groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carl Gommoll, MS, Sr. Dir. Clinical Development Psychiatry</name_or_title>
      <organization>Forest Research Institute</organization>
      <phone>201-427-8000 ext 8124</phone>
      <email>carl.gommoll@frx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

